Labcorp (LH)
Technical, fundamental, and sentiment analysis with recent related videos.
LH rates Bullish overall. The fundamental read is bullish: the company passes 8 of 9 quality tests on the Piotroski F-Score; balance sheet is in the Safe zone (Altman Z = 3.38); revenue is declining about 1.4% per year; net income is growing about 9.6% per year. The technical picture is bullish: price is 15.7% above the 200-day moving average; 2.6% above the 50-day; the 50/200 relationship is in a Golden cross. Sentiment is bullish (composite 78/100), based on 8 news articles from recent coverage.
Revenue 3-year avg -1.4%. Net income 3-year avg +9.6%.
Price vs 20DMA +4.2%. RSI 62.81. Bollinger state: Inside Bands.
Composite score 78/100 from the AI judge, based on 8 news items, 0 television segments, and 0 videos.
Latest Market Read
Fundamental is Bullish because net income averaged 9.6 percent per year over three years even though revenue averaged -1.4 percent per year; the net income trend carries the label. Technical is Bullish: price sits about 4.2 percent above its 20-day moving average, the Relative Strength Index (RSI), a momentum reading, is 62.8, and the stock trades inside its Bollinger Bands. Sentiment is Bullish with a 78/100 composite. All three Bullish badges produce an Overall Bullish rating.
Recent news: The coverage is largely positive, highlighting a near-term shareholder return and material commercial wins: Labcorp declared a $0.72/share dividend payable Dec 11, 2026, and struck a Waters partnership to roll out the FDA‑approved BD Onclarity HPV Assay nationwide with Labcorp set to be the first commercial lab to offer clinician, self‑collected, and at‑home testing starting in late 2026. Additional items note a 355% increase in Robeco's stake and new product and testing initiatives, while one article questions valuation and whether future cash flows are already priced in, and the GDELT tone is neutral‑leaning (46/100).
Latest Videos
- No qualified videos yet.